Arbutus Biopharma Corpora...

NASDAQ: ABUS · Real-Time Price · USD
3.35
-0.02 (-0.59%)
At close: Aug 15, 2025, 1:14 PM
-0.59%
Bid 3.34
Market Cap 642.19M
Revenue (ttm) 15.42M
Net Income (ttm) -54.25M
EPS (ttm) -0.29
PE Ratio (ttm) -11.55
Forward PE -17.87
Analyst Buy
Ask 3.36
Volume 336,447
Avg. Volume (20D) 750,061
Open 3.41
Previous Close 3.37
Day's Range 3.34 - 3.45
52-Week Range 2.71 - 4.72
Beta 0.86

About ABUS

undefined

Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ABUS
Website n/a
Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for ABUS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Arbutus Biopharma has released their quartely earnings on Aug 6, 2025:
  • Revenue of $10.74M exceeds estimates by $8.69M, with 522.19% YoY growth.
  • EPS of 0.01 exceeds estimates by 0.07, with 109.09% YoY growth.
  • Next Earnings Release

    Arbutus Biopharma Corporation is scheduled to release its earnings on Nov 5, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription
    3 months ago
    -0.9%
    ABUS stock has given up its prior gain. Arbutus Bi... Unlock content with Pro Subscription
    3 months ago
    -0.9%
    Arbutus Biopharma shares are trading higher after the company presented clinical trial data from its two HBV assets.